Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Pharma News: Vivus, Inc. (VVUS), Arena Pharmaceuticals, Inc. (ARNA)’s Announcement & MannKind Corporation (MNKD)’s New Options

Editor’s Note: Related tickers: VIVUS, Inc. (NASDAQ:VVUS), Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), MannKind Corporation (NASDAQ:MNKD), J.C. Penney Company, Inc. (NYSE:JCP)

3 Pharmaceutical Stocks to Sell Now (InvestorPlace)
This week, the ratings of three Pharmaceutical stocks on Portfolio Grader are down. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”). This week, VIVUS, Inc. (NASDAQ:VVUS) falls to a D (“sell”), worse than last week’s grade of C (“hold”). VIVUS is a biopharmaceutical company engaged in the development and commercialization of therapeutic products for large underserved markets. VVUS also rates an F in Portfolio Grader’s specific subcategory of Equity. The stock price has dropped 17.4% over the past month, worse than the 1.3% decrease the Nasdaq has seen over the same period of time.

VIVUS, Inc. (NASDAQ:VVUS)

Eye Catching Stocks for Friday’s Trading Session: Arena Pharmaceuticals Inc (ARNA), J.C. Penney Company Inc (JCP) (SBWire)
Pennystocksupdate.biz issues special report on – Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), J.C. Penney Company, Inc. (NYSE:JCP) Arena Pharmaceuticals Inc (NASDAQ: ARNA) may have triggered an individual to create heart disease in an early-stage medical query, the company refers to, one day after introducing there had not been any serious adverse reactions during the research. Arena Pharmaceuticals, Inc. (ARNA) after opening at $6.55 hit a high price of $6.58 and then closed at $6.35 by declining -5.08% and on last session volume of 8.68 million shares was surprisingly lower than its average volume of 4.24 million shares.

MannKind Corp. VP Unloads $110,999.12 in Stock (MNKD) (WatchlistNews)
MannKind Corporation (NASDAQ:MNKD) VP David Thomson sold 19,204 shares of MannKind Corp. stock in a transaction that occurred on Wednesday, August 28th. The stock was sold at an average price of $5.78, for a total transaction of $110,999.12. Following the sale, the vice president now directly owns 40,082 shares in the company. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. A number of analysts have recently weighed in on MNKD shares. Analysts at MLV Capital raised their price target on shares of MannKind Corporation (NASDAQ:MNKD).

Commit To Purchase Vivus At $8, Earn 17.1% (Forbes)
Investors considering a purchase of VIVUS, Inc. (NASDAQ:VVUS) shares, but cautious about paying the going market price of $12.25/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the January 2015 put at the $8 strike, which has a bid at the time of this writing of $1.37. Collecting that bid as the premium represents a 17.1% return against the $8 commitment, or a 12.3% annualized rate of return (at Stock Options Channel we call this the YieldBoost).

Arena Reports Closing of Phase 1b Clinical Trial for APD811; Astex Shares On Watch Following Positive Top-Line Data for SGI-0110 (HispanicBusiness)
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) announced the completion of a Phase 1b clinical trial for APD811, an investigational oral prostacyclin (IP) receptor agonist intended for the treatment of pulmonary arterial hypertension (PAH). The company plans to initiate a Phase 2 clinical trial for APD811 in the first quarter of 2014. “Arena’s internal GPCR-focused efforts led to the discovery of this novel drug candidate,” said William R. Shanahan, M.D., Arena’s Senior Vice President and Chief Medical Officer…

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading...